---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-25-000018"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:20:18.052210+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen Q1 beats: revenue $8.1B (+9%), non-GAAP EPS $4.90 (+24%), FCF $1.0B

## Summary
- GAAP EPS $3.20 vs -$0.21; includes $800M Otezla intangible impairment.
- Non-GAAP EPS $4.90 (+24% YoY) on revenue $8.1B (+9%).
- Product sales up 11% with 14% volume growth; 14 products had double-digit growth.
- Free cash flow $1.0B vs $0.5B prior year, driven by business performance.
- IMDELLTRA sales $81M; Phase 3 confirmatory trial improved overall survival vs chemo.

## SEC filing metadata
- accession: 0000318154-25-000018
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/0000318154-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/amgn-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-25-000018
- JSON: https://secwatch.observer/filing/0000318154-25-000018.json
- Plain text: https://secwatch.observer/filing/0000318154-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.